# Nuformix first patent in relation to NXP004 to the publication stage

- Link: https://www.directorstalkinterviews.com/nuformix-first-patent-in-relation-to-nxp004-to-the-publication-stage/4121058504
- Published: 2022-03-28T07:40:17+01:00
- Author: Amilia Stone

**Nuformix plc **([LON:NFX](https://www.directorstalkinterviews.com/company/nuformix-plc/nfx.l)),
a pharmaceutical development company targeting unmet medical needs in fibrosis and
oncology via drug repurposing, has announced the publication of an international
patent in relation to the Company’s NXP004 asset, which comprises novel forms of
olaparib.  Olaparib is currently marketed by AstraZeneca, under the Lynparza® brand
name for the treatment of adults with suspected deleterious germline or somatic 
BRCA gene mutated ovarian, breast, or pancreatic cancer, or for suspected deleterious
germline or somatic HRR gene mutated prostate cancer.

The application for the Patent, relating to new olaparib oxalic acid cocrystals,
their therapeutic uses and pharmaceutical compositions containing them, was made
by the Company’s wholly owned subsidiary Nuformix Technologies Limited and was filed
in September 2020.  The Company filed a second patent application, complementing
the Patent, in November 2021 and this remains pending.

The olaparib oxalic acid cocrystals covered by the Patent may be used in the same
way as olaparib. Olaparib is useful in treating diseases that benefit from PARP (
Poly ADP Ribose Polymerase) inhibition. These include cancer, fibrosis, inflammatory
conditions (e.g. asthma, colitis, arthritis), neurological diseases (e.g. neurodegeneration,
neurotrauma, stroke), cardiovascular conditions, ophthalmic degenerative diseases,
vascular diseases (e.g. diabetic complications, atherosclerosis), and various forms
of critical illness (e.g. septic shock, ALI, acute liver failure). The olaparib 
oxalic acid cocrystals covered by the Patent may, therefore, ultimately be useful
for the treatment of such diseases, disorders, and conditions.

The Company looks forward to providing further updates on progress with NXP004 and
the Company’s other assets in due course.

> **Commenting, Alastair Riddell, Executive Chairman of Nuformix, said:** “We are
> pleased to see the progression of the application for the Company’s first patent
> in relation to NXP004 to the publication stage.  We believe NXP004 has significant
> potential and look forward to the granting of the Patent in due course.  We are
> continuing to conduct further research and development activities on NXP004, as
> well as investigating future commercial opportunities.  Whilst there remains much
> to be done, I look forward to making further announcements on our progress in 
> the future.”

Share on: